Which country is ecmo made in?

By March 2020, the mainstream brands of extracorporeal membrane oxygenation in the domestic market are mainly Medtronic, Midos, McVeigh and Sorin in Europe and America. According to the data of the Professional Committee of Extracorporeal Life Support of Chinese Medical Doctor Association, by the end of 20 18, there were more than 400 extracorporeal membrane oxygenation devices in China, among which the products of McVeigh and Sorin occupied the vast majority of the domestic market.

The world's top three suppliers of extracorporeal membrane oxygenation in China market: German McVeigh belongs to Swedish Gettin Group, accounting for more than 70% of the China market;

Followed by Medtronic (10%); In addition, Sorin belongs to Livanova, accounting for 10%. Other manufacturers include Telmao Terumo and Midos Medos (belonging to Eus Fresenius in Fei Sen).

China company is ready to go, and has begun to surge in a generally promising market, but so far there is no real domestic in vitro membrane lung oxygen synthesis product.

Extended data:

From 65438 to 0953, Dr. Gibbon invented the artificial heart-lung machine, and he successfully applied the cardiopulmonary bypass technology to clinical heart surgery for the first time, making it possible for the artificial heart-lung machine system to assist the heart and lungs for a long time. Extracorporeal membrane oxygenation (extracorporeal membrane oxygenation) is actually an extension of cardiopulmonary bypass technology, and it has been used to treat life-threatening respiratory failure for more than 20 years.

1960 ~ 1970 saw the appearance of membrane oxygenator. 1965 ~ 1975 saw the perfection of anticoagulation control technology, which made it possible to popularize and use the extracorporeal circulation technology. Membrane oxygenator uses semi-permeable membrane to separate blood from gas, which protects red blood cells and platelets and makes it possible for extracorporeal membrane oxygenation to exist for a long time.

In 197 1 year, Dr. Hill first treated 1 24-year-old male patient with extracorporeal membrane oxygenation. Due to multiple trauma, respiratory failure gradually worsened. After 75 hours of extracorporeal membrane oxygenation, the patient was out of danger and was successfully rescued. So some hospitals began extracorporeal membrane oxygenation one after another, but it soon ended because of the low success rate.

1975, Dr. Bartlett successfully treated 1 newborn with persistent fetal circulation with extracorporeal membrane oxygenation for the first time. Since then, the application experience of extracorporeal membrane oxygenation technology in newborns has increased rapidly. Nowadays, people think that extracorporeal membrane oxygenation is the standard method to treat severe respiratory failure in newborns and infants.

1993 zwushenberger et al investigated 5000 children with respiratory failure who received extracorporeal membrane oxygenation. The results showed that the survival rate was 82%, while the mortality rate of conventional treatment was 80%. This aroused people's enthusiasm for research, and made a phased summary in 1994: extracorporeal membrane oxygenation is better for newborns than adults, and better for respiratory failure than for heart failure.

With the continuous development of medical technology, material technology and mechanical technology, the support time of extracorporeal membrane oxygenation is prolonged and the curative effect of adults is improved, so it is more widely used in clinical critical first aid. Even some medical centers set extracorporeal membrane oxygenation equipment as the basic configuration of ambulances, so that extracorporeal membrane oxygenation can go to hospitals and better play its first-aid function.

References:

People's Daily Online-Where is the difficulty in localization of extracorporeal membrane oxygenation that relies entirely on imported "life-saving artifacts"?